Globus Medical Company Profile (NYSE:GMED)

About Globus Medical (NYSE:GMED)

Globus Medical logoGlobus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company's products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company sells its products through exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:GMED
  • CUSIP: 37957720
  • Web:
  • Market Cap: $2.91 billion
  • Outstanding Shares: 96,291,000
Average Prices:
  • 50 Day Moving Avg: $29.91
  • 200 Day Moving Avg: $30.89
  • 52 Week Range: $19.25 - $34.03
  • Trailing P/E Ratio: 26.49
  • Foreward P/E Ratio: 21.71
  • P/E Growth: 2.17
Sales & Book Value:
  • Annual Revenue: $595.44 million
  • Price / Sales: 4.88
  • Book Value: $9.40 per share
  • Price / Book: 3.21
  • EBITDA: $207.13 million
  • Net Margins: 18.12%
  • Return on Equity: 13.99%
  • Return on Assets: 12.63%
  • Current Ratio: 7.75%
  • Quick Ratio: 6.14%
  • Average Volume: 679,639 shs.
  • Beta: 0.56
  • Short Ratio: 19.21

Frequently Asked Questions for Globus Medical (NYSE:GMED)

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) released its earnings results on Wednesday, August, 2nd. The company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.30 by $0.02. The company earned $152.39 million during the quarter, compared to the consensus estimate of $150.94 million. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The company's revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.29 EPS. View Globus Medical's Earnings History.

When will Globus Medical make its next earnings announcement?

Globus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Globus Medical.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY17 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of $1.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.27. The company issued revenue guidance of $625 million, compared to the consensus revenue estimate of $625.81 million.

Where is Globus Medical's stock going? Where will Globus Medical's stock price be in 2017?

12 brokerages have issued 1-year target prices for Globus Medical's stock. Their forecasts range from $23.00 to $38.00. On average, they expect Globus Medical's stock price to reach $30.71 in the next year. View Analyst Ratings for Globus Medical.

What are analysts saying about Globus Medical stock?

Here are some recent quotes from research analysts about Globus Medical stock:

  • 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (10/4/2017)
  • 2. Needham & Company LLC analysts commented, "GMED’s core spine organic growth has slowed though we expect some improvement in 2018 due to sales force enhancements. Its Emerging Technologies business should begin to add to growth in 2018 as well. But even accounting for this, we’re concerned that consensus 2018 estimates may be too high. And we believe that GMED’s earnings growth is going to be mostly driven by revenue growth." (9/26/2017)
  • 3. Barclays PLC analysts commented, "ELGX’s 2Q17 sales of $48.6M (-4.7%) came in ahead of our/consensus estimates of $47.6M; higher OUS sales offset lighter US results impacted by sales force attrition and lower AFX2 sales recapture. Ovation growth remained strong. Net loss was better on higher sales, better GM, and lower opex. ELGX lowered FY17 guidance by $9M at the midpoint to $185-190M on lower AFX2 sales recapture and sales force attrition. ELGX expects to begin PMA enrollment for Gen2 Nellix in late 2017/early 2018. We expect a slight uptick in 2H17 sales as AFX2 US softness continues, offset by Ovation US growth. We assume higher growth in ’18 versus ’17 on easier ’17 comps from both AFX manufacturing issues and the narrowed Nellix IFU." (8/3/2017)
  • 4. Aegis analysts commented, "GMED reported 4Q16 non-GAAP EPS and revenues of $0.31 and $151.6 million (6.3%/6.5% cc), respectively, with EPS 2 cents short of our and consensus estimates and revenues in line with preliminary reported revenues. Gross margins for the quarter were 74.3%, down from 75.4% in 4Q15 due to one-time accounting adjustments and acquisition-related costs. Despite increasing investments, management maintained strong non-GAAP adjusted EBITDA margins of 37.7% though non-GAAP EPS fell short by 2 cents. During the call management emphasized that sales force issues are now behind them and, most importantly, that they expect to see a return to positive organic US growth in 1Q17. Management believes that this is the inflection point and is re-affirming FY2017 guidance of $625 million in revenues and $1.27 in EPS ' roughly 6.4% organic top-line growth. We believe US approval of its Excelsius GPS robot (expected by mid-year) and build out of its trauma business will provide upside to the business, where management is assuming a modest $10 million in emerging technologies contribution in 2017. We re-iterate our Buy rating and $31 TP." (2/28/2017)

Who are some of Globus Medical's key competitors?

How do I buy Globus Medical stock?

Shares of Globus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Globus Medical's stock price today?

One share of Globus Medical stock can currently be purchased for approximately $30.18.

MarketBeat Community Rating for Globus Medical (NYSE GMED)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  213 (Vote Underperform)
Total Votes:  507
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Globus Medical (NYSE:GMED) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $30.71 (1.77% upside)
Consensus Price Target History for Globus Medical (NYSE:GMED)
Price Target History for Globus Medical (NYSE:GMED)
Analysts' Ratings History for Globus Medical (NYSE:GMED)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017Needham & Company LLCInitiated CoverageHoldHighView Rating Details
9/22/2017Canaccord GenuityReiterated RatingBuy$38.00LowView Rating Details
9/7/2017BTIG ResearchInitiated CoverageBuy$37.00LowView Rating Details
8/30/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
8/9/2017Barclays PLCReiterated RatingUnderweight$30.00 -> $28.00LowView Rating Details
8/4/2017GabelliReiterated RatingBuyLowView Rating Details
7/11/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
4/12/2017Leerink SwannUpgradeMarket Perform -> OutperformHighView Rating Details
2/28/2017AegisReiterated RatingBuy$31.00N/AView Rating Details
11/9/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
11/9/2016Citigroup Inc.DowngradeMarket Perform$29.00 -> $23.00N/AView Rating Details
11/9/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
7/27/2016Wells Fargo & CompanyDowngradeOutperform -> Market Perform$23.00N/AView Rating Details
6/25/2016Piper Jaffray CompaniesReiterated RatingOverweight$29.00N/AView Rating Details
5/26/2016Goldman Sachs Group, Inc. (The)DowngradeNeutral -> Sell$21.00N/AView Rating Details
5/4/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/8/2016Bank of America CorporationDowngradeBuy -> Underperform$28.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Globus Medical (NYSE:GMED)
Earnings by Quarter for Globus Medical (NYSE:GMED)
Earnings History by Quarter for Globus Medical (NYSE GMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017$0.30N/AView Earnings Details
8/2/2017Q2 2017$0.30$0.32$150.94 million$152.39 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.31$0.32$155.81 millionViewListenView Earnings Details
2/27/2017Q416$0.33$0.31$149.30 million$151.59 millionViewListenView Earnings Details
11/8/2016Q3$0.28$0.29$139.25 million$135.70 millionViewListenView Earnings Details
7/26/2016Q2$0.29$0.29$141.78 million$137.49 millionViewListenView Earnings Details
5/3/2016Q1$0.28$0.29$140.30 million$139.30 millionViewListenView Earnings Details
2/24/2016Q4$0.30$0.32$141.20 million$142.60 millionViewListenView Earnings Details
11/3/2015Q3$0.25$0.28$127.46 million$137.00 millionViewListenView Earnings Details
7/30/2015Q215$0.25$0.25$126.89 million$133.60 millionViewListenView Earnings Details
5/5/2015Q115$0.24$0.26$122.30 million$131.60 millionViewListenView Earnings Details
2/25/2015Q414$0.25$0.30$127.77 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.21$0.24$113.10 million$117.80 millionViewListenView Earnings Details
8/5/2014Q214$0.23$0.23$119.83 million$113.60 millionViewListenView Earnings Details
4/29/2014Q114$0.22$0.24$113.59 million$114.20 millionViewListenView Earnings Details
2/26/2014Q413$0.22$0.25$114.96 million$115.20 millionViewListenView Earnings Details
10/30/2013Q313$0.19$0.22$106.00 million$107.19 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.20$0.21$107.46 million$107.00 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.21$103.14 million$105.00 millionViewListenView Earnings Details
2/27/2013Q4 2012$0.19$0.22$99.13 million$100.50 millionViewListenView Earnings Details
11/1/2012Q312$0.19$0.18$95.32 million$94.76 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Globus Medical (NYSE:GMED)
Current Year EPS Consensus Estimate: $1.27 EPS
Next Year EPS Consensus Estimate: $1.39 EPS


Dividend History for Globus Medical (NYSE:GMED)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Globus Medical (NYSE:GMED)
Insider Ownership Percentage: 28.21%
Institutional Ownership Percentage: 65.40%
Insider Trades by Quarter for Globus Medical (NYSE:GMED)
Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)
Insider Trades by Quarter for Globus Medical (NYSE:GMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2017A Brett MurphyInsiderSell15,000$29.99$449,850.00View SEC Filing  
6/5/2017Anthony L WilliamsPresidentSell16,153$31.94$515,926.82View SEC Filing  
8/5/2016A Brett MurphyInsiderSell107,692$23.37$2,516,762.04View SEC Filing  
1/6/2016Robert LiptakDirectorSell15,300$27.50$420,750.00View SEC Filing  
1/4/2016Kurt WheelerDirectorSell255$27.50$7,012.50View SEC Filing  
5/28/2015Steven PayneCAOSell3,076$25.92$79,729.92View SEC Filing  
3/19/2015David C PaulCEOSell1,922,000$25.00$48,050,000.00View SEC Filing  
1/15/2014David DemskiCOOSell96,813$20.51$1,985,634.63View SEC Filing  
12/31/2013David DemskiCOOSell3,187$20.25$64,536.75View SEC Filing  
12/20/2013David DemskiCOOSell50,000$19.75$987,500.00View SEC Filing  
12/6/2013Robert LiptakDirectorSell25,000$19.36$484,000.00View SEC Filing  
12/3/2013David DavidarVPSell75,000$19.25$1,443,750.00View SEC Filing  
11/27/2013David DemskiCOOSell37,323$19.25$718,467.75View SEC Filing  
11/1/2013David M DemskiCOOSell112,677$18.59$2,094,665.43View SEC Filing  
8/23/2013David DavidarVPSell7,278$18.20$132,459.60View SEC Filing  
8/22/2013David DemskiCOOSell44,154$17.95$792,564.30View SEC Filing  
7/5/2013David D DavidarVPSell10,000$17.15$171,500.00View SEC Filing  
7/1/2013David D DavidarVPSell20,000$16.56$331,200.00View SEC Filing  
6/26/2013David D DavidarVPSell150,000$16.71$2,506,500.00View SEC Filing  
8/8/2012David C PaulCEOSell3,039,385$11.16$33,919,536.60View SEC Filing  
8/8/2012David D DavidarVPSell166,885$11.16$1,862,436.60View SEC Filing  
8/8/2012David M DemskiCOOSell98,957$11.16$1,104,360.12View SEC Filing  
8/8/2012Kurt WheelerDirectorSell804,232$11.16$8,975,229.12View SEC Filing  
8/8/2012Steven PayneCAOSell2,305$11.16$25,723.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Globus Medical (NYSE:GMED)
Latest Headlines for Globus Medical (NYSE:GMED)
DateHeadline logoGlobus Medical Schedules Third Quarter 2017 Earnings Release and Conference Call - October 17 at 4:39 PM logoGlobus Medical, Inc. (GMED) Downgraded by BidaskClub - October 14 at 8:22 AM logoGlobus Medical (GMED) Reports First Spine Surgeries Using ExcelsiusGPS - October 12 at 3:20 AM logoGlobus Medical, Inc. (GMED) Receives Consensus Recommendation of "Hold" from Analysts - October 11 at 4:50 AM logoGlobus Medical Announces First Spine Surgeries Using ExcelsiusGPS™ - October 10 at 8:20 PM logoGlobus Medical, Inc. (GMED) Upgraded at BidaskClub - October 7 at 10:44 AM logoGlobus Medical, Inc. (GMED) Upgraded to Hold at Zacks Investment Research - October 4 at 9:50 PM logoGlobus Medical, Inc. – Value Analysis (NYSE:GMED) : October 4, 2017 - October 4 at 12:06 PM logoGlobus Medical, Inc. breached its 50 day moving average in a Bullish Manner : GMED-US : October 3, 2017 - October 3 at 9:11 AM logoGlobus Medical, Inc. (GMED) Expected to Announce Earnings of $0.30 Per Share - September 30 at 4:28 AM logoGlobus Medical, Inc. (GMED) Coverage Initiated by Analysts at Needham & Company LLC - September 26 at 7:34 PM logoGlobus Medical, Inc. (GMED) Receives Buy Rating from Canaccord Genuity - September 22 at 8:26 PM logoNotable Two Hundred Day Moving Average Cross - GMED - September 22 at 7:24 PM logoHead-To-Head Review: Globus Medical (GMED) vs. Arch Therapeutics (ARTH) - September 16 at 10:32 AM logoGlobus Medical, Inc. (GMED) Receives Average Recommendation of "Hold" from Analysts - September 16 at 4:42 AM logoGlobus Medical, Inc. breached its 50 day moving average in a Bearish Manner : GMED-US : September 14, 2017 - September 14 at 7:44 PM logoGlobus Medical Announces First Case in Orthopedic Trauma - September 14 at 7:44 PM logoGlobus Medical (GMED) & Arch Therapeutics (ARTH) Head to Head Review - September 13 at 8:12 PM logoContrasting Globus Medical (GMED) and Arch Therapeutics (ARTH) - September 13 at 6:44 PM logoGlobus Medical, Inc. (GMED) Expected to Announce Quarterly Sales of $152.00 Million - September 13 at 11:42 AM logoIBD Rating Upgrades: Globus Medical Shows Improved Price Strength - September 11 at 7:36 PM logo$0.30 EPS Expected for Globus Medical, Inc. (GMED) This Quarter - September 11 at 10:38 AM logoStocks Under Scanner in the Medical Equipment Space -- Globus Medical ... - September 8 at 12:19 AM logoGlobus Medical, Inc. (GMED) Insider A Brett Murphy Sells 15,000 Shares - September 7 at 7:42 PM logoGlobus Medical, Inc. (GMED) Now Covered by BTIG Research - September 7 at 1:00 PM logoComparing Arch Therapeutics (ARTH) and Globus Medical (GMED) - September 5 at 2:22 AM logoMedical device manufacturer makes CEO change as chairman recovers from 'health condition' - August 30 at 4:27 PM logoOppenheimer Holdings, Inc. Reaffirms "Hold" Rating for Globus Medical, Inc. (GMED) - August 30 at 12:42 PM logoGlobus Medical Appoints David M. Demski as CEO - August 29 at 7:35 PM logoFirst Week of October 20th Options Trading For Globus Medical - August 27 at 11:11 PM logoGlobus Medical, Inc. (GMED) Expected to Post Quarterly Sales of $152.00 Million - August 25 at 3:44 AM logo Analysts Anticipate Globus Medical, Inc. (GMED) Will Announce Earnings of $0.30 Per Share - August 23 at 8:24 PM logoETFs with exposure to Globus Medical, Inc. : August 21, 2017 - August 23 at 7:39 AM logoGlobus Medical, Inc. (GMED) Given Average Rating of "Hold" by Brokerages - August 22 at 4:28 AM logoArch Therapeutics (ARTH) and Globus Medical (GMED) Head-To-Head Comparison - August 22 at 2:10 AM logoGlobus Medical, Inc. (GMED) Stock Rating Reaffirmed by Canaccord Genuity - August 19 at 6:28 AM logoGlobus Medical's Robotic Guidance System Gets FDA Approval - August 18 at 6:58 PM logoGlobus Medical Announces FDA 510(k) Clearance for Excelsius GPS™ - August 18 at 2:34 AM logoGlobus Medical (GMED) Stock is Popping: Here's Why - August 18 at 2:33 AM logoComparing Globus Medical (GMED) & Medtronic PLC (MDT) - August 13 at 8:10 PM logoGlobus Medical, Inc. :GMED-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 - August 11 at 12:27 AM logoSee what the IHS Markit Score report has to say about Globus Medical Inc. - August 9 at 7:15 PM logoReviewing Globus Medical (GMED) & Integer Holdings (ITGR) - August 6 at 10:18 PM logoFinancial Comparison: Globus Medical (GMED) and AxoGen (AXGN) - August 6 at 8:06 AM logoGlobus Medical, Inc. (NYSE:GMED) Rating Reiterated by Gabelli - August 4 at 11:50 AM logoGlobus Medical, Inc. (GMED) Announces Earnings Results - August 3 at 11:20 PM logoGlobus Medical is Now Oversold (GMED) - August 3 at 9:17 PM logoGlobus Medical (GMED) Q2 2017 Results - Earnings Call Transcript - August 3 at 9:17 PM logoBarclays PLC Reaffirms Sell Rating for Globus Medical, Inc. (NYSE:GMED) - August 3 at 4:44 PM logoEdited Transcript of GMED earnings conference call or presentation 2-Aug-17 9:30pm GMT - August 3 at 4:11 PM



Globus Medical (GMED) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.